查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球连接酶市场（按类型、来源、等级、分子生物学工作流程和应用）预测至 2030 年
市场调查报告书
商品编码
1830049

全球连接酶市场（按类型、来源、等级、分子生物学工作流程和应用）预测至 2030 年

Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030
出版日期: | 出版商: MarketsandMarkets | 英文 311 Pages | 订单完成后即时交付

价格

全球连接酶市场预计将从 2025 年的 2.6 亿美元成长到 2030 年的 3.6 亿美元，预测期间的复合年增长率为 6.8%。

调查范围
调查年份 2024-2030
基准年 2024
预测期 2025-2030
单元 10亿美元
部分 类型、来源、等级、分子生物学工作流程、应用、最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

连接酶市场的成长得益于基因组学和次世代定序(NGS) 的日益普及、分子诊断和个人化医疗的扩展以及合成生物学应用的日益增长。连接酶在 NGS 工作流程中发挥核心作用，能够实现接头连接和文库构建，使其成为大规模基因组学计划和精准医疗工作的关键。分子诊断和精准医疗领域应用的不断拓展也有望推动市场成长。

连接酶市场-IMG1

根据等级，GMP 级连接酶部分预计在预测期内达到最高的复合年增长率。

这一增长主要源于治疗药物生产、基因治疗和临床应用对GMP级连接酶日益增长的需求，这些应用领域必须遵守严格的品质和安全标准。此外，细胞和基因治疗、生物製药生产以及诊断检测方法开发等领域的投资不断增加，预计也将推动市场成长。

根据来源，病毒衍生部分在 2024 年占据了最大的市场份额。

病毒连接酶在2024年占据了最大的市场份额，这得益于其在分子生物学工作流程中的广泛应用，尤其是在克隆、DNA修復研究和次世代定序（NGS）样品製备等应用中。病毒连接酶（例如T4 DNA连接酶）因其在催化DNA片段连接方面的高效性而成为行业标准，使其成为研究和工业生物技术中必不可少的物质。

按地区划分，预计亚太市场在预测期内的复合年增长率最高。

预计亚太地区在预测期内将实现最高的复合年增长率，这得益于基因组研究投资的增加、生物技术和製药行业的扩张以及对精准医疗日益增长的关注。中国、日本、韩国和印度正在透过政府资助、官民合作关係和国际合作大幅提升其研发能力，对包括连接酶在内的分子生物学工具的需求强劲。次世代定序(NGS)、合成生物学以及癌症、感染疾病和罕见遗传疾病的分子诊断技术的日益普及也进一步推动了市场扩张。

本报告分析了全球连接酶市场，提供了关键驱动因素和限制因素、竞争格局和未来趋势的资讯。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 主要发现

  • 全球连结酵素市场概况
  • 北美连接酶市场（按类型和国家划分）（2024 年）
  • 连接酶市场类型（2024）
  • 连接酶市场（按最终用户划分）（2024 年）
  • 连结酵素市场：地理成长机会
  • 未满足的需求和閒置频段
  • 成长机会的策略分析
  • 新的经营模式和生态系统变化
  • 永续性影响和监管政策倡议

第五章 市场概况

  • 介绍
  • 市场动态
    • 驱动程式
    • 抑制因素
    • 机会
    • 任务

第六章 产业趋势

  • 影响客户业务的趋势/中断
    • 转向高通量自动化工作流程
    • 扩大连接酶在快速和即时检测的应用
  • 价值链分析
  • 生态系分析
  • 技术分析
    • 主要技术
    • 互补技术
  • 专利分析
    • 调查方法
    • 专利申请和授权数量（2014-2024）
  • 贸易分析
    • 进口资料（HS编码350790）
    • 出口资料（HS编码350790）
  • 波特五力分析
  • 关税和监管格局
    • 海关资料（HS编码350790）
    • 监管机构、政府机构和其他组织
    • 法规结构
  • 定价分析
    • 主要企业连接酶平均售价趋势（2022-2024）
    • 各地区连接酶平均售价（2024年）
  • 大型会议和活动（2025-2026）
  • 主要相关利益者和采购标准
    • 采购过程中的关键相关利益者
    • 相关利益者在采购过程中的作用
    • 采购标准
  • 投资金筹措场景
  • 人工智慧/产生人工智慧对连接酶市场的影响
    • 人工智慧用例
    • 采用人工智慧的主要企业
    • 人工智慧的未来
  • 2025年美国关税对连结酶市场的影响
    • 介绍
    • 主要关税税率
    • 价格影响分析
    • 对国家的影响
    • 对终端产业的影响

7. 连接酶市场（按类型）

  • 介绍
  • DNA连接酶
  • RNA连接酶
  • 其他连接酶

8. 连接酶市场（依来源）

  • 介绍
  • 病毒连接酶
  • 细菌连接酶
  • 真核生物连接酶
  • 古细菌连接酶

9. 连接酶市场（依等级）

  • 介绍
  • RUO级连接酶
  • GMP级连接酶
  • 诊断级连接酶

10. 依分子生物学工作流程分類的连结酶市场

  • 介绍
  • 克隆和诱变
  • 合成生物学
  • 定序
  • 核酸扩增

第11章连接酶市场（依应用）

  • 介绍
  • 研究用途
  • 诊断用途
  • 治疗药物开发与製造
  • 其他用途

第 12 章 连接酶市场（依最终用户）

  • 介绍
  • 学术和研究机构
  • 製药和生物技术公司
  • 医院和诊断实验室
  • 医疗设备公司

第十三章按地区分類的连结酶市场

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东
    • 中东宏观经济展望
    • 海湾合作委员会国家
    • 其他中东地区
  • 非洲

第十四章竞争格局

  • 概述
  • 主要参与企业的策略/优势（2021-2025）
  • 收益分析（2020-2024）
  • 市占率分析（2024年）
  • 企业评估矩阵：主要企业（2024年）
  • 公司评估矩阵：Start-Ups/中小企业（2024 年）
  • 公司估值及财务指标
  • 品牌/产品比较
  • 竞争场景

第十五章：公司简介

  • 主要企业
    • NEW ENGLAND BIOLABS
    • THERMO FISHER SCIENTIFIC INC.
    • QIAGEN NV
    • PROMEGA CORPORATION
    • TAKARA BIO INC.
    • DANAHER CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • MERCK KGAA
    • ARCTICZYMES TECHNOLOGIES
    • BIOSYNTH
    • HIMEDIA LABORATORIES
    • LGC BIOSEARCH TECHNOLOGIES
    • INSPIRALIS LIMITED
    • BIONEER CORPORATION
  • 其他公司
    • GENO TECHNOLOGY INC.
    • MBR, INC.
    • ABCLONAL, INC.
    • NZYTECH
    • JENA BIOSCIENCE GMBH
    • CREATIVE ENZYMES.
    • ENZYNOMICS CO., LTD.
    • BIOCAT GMBH
    • GENAXXON BIOSCIENCE
    • MERIDIAN BIOSICENCE
    • CANVAX
    • BIOTECHRABBIT
    • MCLAB

第十六章 附录

Product Code: BT 9495

The ligase enzymes market is expected to reach USD 0.36 billion in 2030 from USD 0.26 billion in 2025, at a CAGR of 6.8% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsType, Source, Grade, Molecular Biology Workflow, Application, and End User
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

The growth of the ligase enzymes market is driven by the rising adoption of genomics and next-generation sequencing (NGS), the expansion of molecular diagnostics and personalized medicine, and the increasing use of synthetic biology. Ligases play a central role in NGS workflows by enabling adapter ligation & library construction, making them indispensable in large-scale genomics projects and precision medicine initiatives. Its growing application in molecular diagnostics and precision medicine is also expected to fuel the market growth.

Ligase Enzymes Market - IMG1

By grade, the GMP-grade ligase enzymes segment is projected to register the highest CAGR during the forecast period.

By grade, the ligase enzymes market is segmented into Research Use Only (RUO), GMP-grade, and diagnostic-grade ligase enzymes. The GMP-grade ligase enzymes segment is expected to grow at the highest CAGR during the forecast period. The growth is supported by the rising demand for GMP-grade ligase enzymes in therapeutic manufacturing, gene therapy, and clinical applications where compliance with stringent quality and safety standards is essential. The increasing investments in cell & gene therapies, biopharmaceutical production, and diagnostic assay development are also expected to fuel the market growth.

By source, the viral sources segment accounted for the largest share of the market in 2024.

Based on the source, the ligase enzymes market is segmented into viral, bacterial, archaeal, and eukaryotic sources. In 2024, the viral ligases segment accounted for the largest market share owing to its high adoption in applications such as molecular biology workflows, particularly in cloning, DNA repair studies, and next-generation sequencing (NGS) library preparation. Viral ligases, such as T4 DNA ligase, are considered industry standards because of their high efficiency in catalyzing the joining of DNA fragments, making them indispensable in research & industrial biotechnology.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

By region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing investments in genomics research, expansion in biotechnology & pharmaceutical industries, and the rising focus on precision medicine. China, Japan, South Korea, and India are significantly scaling up their R&D capabilities through government funding, public-private partnerships, and international collaborations, creating strong demand for molecular biology tools, including ligase enzymes. The growing adoption of next-generation sequencing (NGS), synthetic biology, and molecular diagnostics for cancer, infectious diseases, and rare genetic disorders further supports market expansion.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
  • By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
  • By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, and the Rest of the World- 15%

Promega Corporation (US), New England Biolabs (UK), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Takara Bio Inc. (Japan) are some of the key players in the ligase enzymes market.

The study includes an in-depth competitive analysis of these key players in the ligase enzymes market and their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the ligase enzymes market by type (DNA, RNA, other ligases), by source (viral, bacterial, archaeal, eukaryotic), by grade (RUO, GMP, diagnostic), by molecular biology workflow (cloning & mutagenesis, synthetic biology, sequencing, nucleic acid amplification), by application (research, diagnostic, therapeutic development & manufacturing, other applications), by end user (academic & research institutes, pharmaceutical and biotechnology companies, hospital & diagnostic laboratories, medical device companies), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the ligase enzymes market, including drivers, trends, challenges, and opportunities. A thorough analysis of leading industry players has been undertaken to provide insights into their business profiles, products, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the ligase enzyme market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the ligase enzyme market and its subsegments. It will also help stakeholders better understand the competitive landscape & gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (rising genomics & NGS activities, growth of molecular diagnostics & personalized medicine, and increasing use in synthetic biology), restraints (dependency on research funding), opportunities (development of thermostable/performance-engineered ligases, development of lyophilized/shelf-stable ligases for point-of-care testing and low-resource markets), and challenges (batch-to-batch variability & quality control, growing adoption of ligase independent cloning) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products of the ligase enzyme market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ligase enzyme market
  • Competitive Assessment: In-depth assessment of market share, growth strategies of leading players like New England Biolabs (UK), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Promega Corporation (US), among others, in the ligase enzymes market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
    • 2.2.2 SEGMENTAL MARKET ASSESSMENT
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

  • 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN LIGASE ENZYMES MARKET
  • 3.3 DISRUPTIVE TRENDS SHAPING LIGASE ENZYMES MARKET
  • 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

  • 4.1 GLOBAL LIGASE ENZYMES MARKET SNAPSHOT
  • 4.2 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE AND COUNTRY (2024)
  • 4.3 LIGASE ENZYMES MARKET, BY TYPE (2024)
  • 4.4 LIGASE ENZYMES MARKET, BY END USER (2024)
  • 4.5 LIGASE ENZYMES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.6 UNMET NEEDS & WHITE SPACES
  • 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
    • 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
  • 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
  • 4.9 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising genomics & NGS activity
      • 5.2.1.2 Growth of molecular diagnostics & personalized medicine
      • 5.2.1.3 Growing use in synthetic biology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Dependence on research funding
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Development of thermostable/performance-engineered ligases
      • 5.2.3.2 Development of lyophilized/shelf-stable ligases for point-of- care testing (POCT) and low-resource markets
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Batch-to-batch variability & quality control
      • 5.2.4.2 Growth in adoption of sequence and ligase-independent cloning (SLIC)

6 INDUSTRY TRENDS

  • 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 6.1.1 SHIFT TOWARD HIGH-THROUGHPUT & AUTOMATED WORKFLOWS
    • 6.1.2 EXPANSION OF LIGASE APPLICATIONS IN RAPID & POINT-OF-CARE TESTING
  • 6.2 VALUE CHAIN ANALYSIS
  • 6.3 ECOSYSTEM ANALYSIS
  • 6.4 TECHNOLOGY ANALYSIS
    • 6.4.1 KEY TECHNOLOGIES
      • 6.4.1.1 Precision fermentation
      • 6.4.1.2 Enzyme engineering & protein design
    • 6.4.2 COMPLEMENTARY TECHNOLOGIES
      • 6.4.2.1 Chromatography & purification technologies
      • 6.4.2.2 Cryopreservation & stabilization technologies
  • 6.5 PATENT ANALYSIS
    • 6.5.1 METHODOLOGY
    • 6.5.2 PATENTS APPLIED & GRANTED, 2014-2024
  • 6.6 TRADE ANALYSIS
    • 6.6.1 IMPORT DATA (HS CODE 350790)
    • 6.6.2 EXPORT DATA (HS CODE 350790)
  • 6.7 PORTER'S FIVE FORCES ANALYSIS
    • 6.7.1 THREAT OF NEW ENTRANTS
    • 6.7.2 THREAT OF SUBSTITUTES
    • 6.7.3 BARGAINING POWER OF SUPPLIERS
    • 6.7.4 BARGAINING POWER OF BUYERS
    • 6.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 6.8 TARIFF & REGULATORY LANDSCAPE
    • 6.8.1 TARIFF DATA (HS CODE 350790)
    • 6.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 6.8.3 REGULATORY FRAMEWORK
  • 6.9 PRICING ANALYSIS
    • 6.9.1 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022-2024
    • 6.9.2 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024
  • 6.10 KEY CONFERENCES & EVENTS, 2025-2026
  • 6.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 6.11.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
    • 6.11.3 BUYING CRITERIA
  • 6.12 INVESTMENT & FUNDING SCENARIO
  • 6.13 IMPACT OF AI/GENERATIVE AI ON LIGASE ENZYMES MARKET
    • 6.13.1 AI USE CASES
    • 6.13.2 KEY COMPANIES IMPLEMENTING AI
    • 6.13.3 FUTURE OF AI
  • 6.14 IMPACT OF 2025 US TARIFFS ON LIGASE ENZYMES MARKET
    • 6.14.1 INTRODUCTION
    • 6.14.2 KEY TARIFF RATES
    • 6.14.3 PRICE IMPACT ANALYSIS
    • 6.14.4 IMPACT ON COUNTRY/REGION
      • 6.14.4.1 US
      • 6.14.4.2 Europe
      • 6.14.4.3 Asia Pacific
    • 6.14.5 END-USE INDUSTRY IMPACT
      • 6.14.5.1 Pharmaceutical & biotechnology companies
      • 6.14.5.2 Medical device companies
      • 6.14.5.3 Academic & research institutes
      • 6.14.5.4 Hospitals & diagnostic laboratories

7 LIGASE ENZYMES MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 DNA LIGASES
    • 7.2.1 HIGH ADOPTION OF DNA LIGASES TO SUPPORT MARKET GROWTH
  • 7.3 RNA LIGASES
    • 7.3.1 GROWING ADOPTION OF RNA SEQUENCING AND DEVELOPMENT IN RNA THERAPEUTICS TO DRIVE MARKET GROWTH
  • 7.4 OTHER LIGASES

8 LIGASE ENZYMES MARKET, BY SOURCE

  • 8.1 INTRODUCTION
  • 8.2 VIRAL LIGASES
    • 8.2.1 WIDE COMMERCIAL USE OF VIRAL LIGASES BY COMPANIES TO SUPPORT MARKET GROWTH
  • 8.3 BACTERIAL LIGASES
    • 8.3.1 HIGH SPECIFICITY AND COMPATIBILITY OF BACTERIAL LIGASES WITH CERTAIN APPLICATIONS TO SUPPORT MARKET GROWTH
  • 8.4 EUKARYOTIC LIGASES
    • 8.4.1 EXPANDING ROLE OF EUKARYOTIC LIGASES IN DNA REPAIR ASSAYS AND CRISPR-MEDIATED GENOME EDITING TO BOOST MARKET
  • 8.5 ARCHAEAL LIGASES
    • 8.5.1 RISING DEMAND FOR HIGH-TEMPERATURE LIGATION METHODS IN PCR CLONING TO FUEL GROWTH

9 LIGASE ENZYMES MARKET, BY GRADE

  • 9.1 INTRODUCTION
  • 9.2 RUO-GRADE LIGASES
    • 9.2.1 LOW COST OF RUO-GRADE LIGASE ENZYMES TO SUPPORT MARKET GROWTH
  • 9.3 GMP-GRADE LIGASES
    • 9.3.1 GROWING PIPELINE FOR DNA AND RNA-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH
  • 9.4 DIAGNOSTIC-GRADE LIGASES
    • 9.4.1 CONTINUOUS PRODUCT INNOVATION TO POSITION DIAGNOSTIC-GRADE LIGASES AS HIGH-OPPORTUNITY GROWTH SEGMENT

10 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW

  • 10.1 INTRODUCTION
  • 10.2 CLONING & MUTAGENESIS
    • 10.2.1 WIDE ADOPTION OF CLONING TECHNIQUES TO SUPPORT MARKET GROWTH
  • 10.3 SYNTHETIC BIOLOGY
    • 10.3.1 GROWING EXPANSION OF SYNTHETIC BIOLOGY IN HEALTHCARE TO DRIVE MARKET GROWTH
  • 10.4 SEQUENCING
    • 10.4.1 INCREASING DEMAND FOR LARGE-SCALE GENOME PROJECTS TO BOOST MARKET GROWTH
  • 10.5 NUCLEIC ACID AMPLIFICATION
    • 10.5.1 GROWING DEMAND FOR RAPID, ACCURATE, AND COST-EFFECTIVE MOLECULAR DIAGNOSTICS TO SUPPORT MARKET GROWTH

11 LIGASE ENZYMES MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 RESEARCH APPLICATIONS
    • 11.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH
  • 11.3 DIAGNOSTIC APPLICATIONS
    • 11.3.1 GROWING DEMAND FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
  • 11.4 THERAPEUTIC DEVELOPMENT & MANUFACTURING
    • 11.4.1 GROWING DEMAND FOR GMP-GRADE ENZYMES IN LARGE-SCALE MANUFACTURING TO PROPEL MARKET GROWTH
  • 11.5 OTHER APPLICATIONS

12 LIGASE ENZYMES MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 ACADEMIC & RESEARCH INSTITUTES
    • 12.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH
  • 12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH
  • 12.4 HOSPITALS & DIAGNOSTIC LABORATORIES
    • 12.4.1 GROWING INTEGRATION OF LIGASE-BASED MOLECULAR DIAGNOSTIC TESTS INTO ROUTINE CARE TO SUPPORT MARKET GROWTH
  • 12.5 MEDICAL DEVICE COMPANIES
    • 12.5.1 GROWING FOCUS ON RAPID, RELIABLE, AND USER-FRIENDLY DIAGNOSTIC DEVICES TO FUEL GROWTH

13 LIGASE ENZYMES MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 13.2.2 US
      • 13.2.2.1 Increasing R&D investments and funding to drive market
    • 13.2.3 CANADA
      • 13.2.3.1 Supportive government policies to propel market growth
  • 13.3 EUROPE
    • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 13.3.2 GERMANY
      • 13.3.2.1 Strong healthcare infrastructure and government-backed genomics initiatives to support market
    • 13.3.3 UK
      • 13.3.3.1 Growing adoption of genomics and presence of advanced research infrastructure to drive demand
    • 13.3.4 FRANCE
      • 13.3.4.1 Growing government funding for R&D to propel market
    • 13.3.5 ITALY
      • 13.3.5.1 Growing research funding to drive market growth
    • 13.3.6 SPAIN
      • 13.3.6.1 Increasing number of biotechnology companies to drive demand
    • 13.3.7 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 13.4.2 CHINA
      • 13.4.2.1 Increasing R&D expenditure to support market growth
    • 13.4.3 JAPAN
      • 13.4.3.1 Advanced biotechnology industry and strong research base to support market growth
    • 13.4.4 INDIA
      • 13.4.4.1 Growing government support in evolving biotechnology sector to boost market
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Increasing government support to boost market
    • 13.4.6 AUSTRALIA
      • 13.4.6.1 Growing biotechnology sector to boost demand
    • 13.4.7 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 13.5.2 BRAZIL
      • 13.5.2.1 Rising focus on biotechnology industry to support market
    • 13.5.3 MEXICO
      • 13.5.3.1 Government support for biopharmaceutical production to drive market
    • 13.5.4 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST
    • 13.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
    • 13.6.2 GCC COUNTRIES
      • 13.6.2.1 Saudi Arabia
        • 13.6.2.1.1 Increasing investments in genomics to drive market
      • 13.6.2.2 United Arab Emirates
        • 13.6.2.2.1 Advancements in biopharmaceutical sector to drive demand
      • 13.6.2.3 Rest of GCC Countries
    • 13.6.3 REST OF MIDDLE EAST
  • 13.7 AFRICA
    • 13.7.1 GROWING FUNDING FOR SUPPORTING RESEARCH INFRASTRUCTURE TO DRIVE MARKET
    • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
  • 14.3 REVENUE ANALYSIS, 2020-2024
  • 14.4 MARKET SHARE ANALYSIS, 2024
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 14.5.5.1 Company footprint
      • 14.5.5.2 Region footprint
      • 14.5.5.3 Type footprint
      • 14.5.5.4 Source footprint
      • 14.5.5.5 Application footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 14.6.5.1 Detailed list of key startups/SMEs
      • 14.6.5.2 Competitive benchmarking of key startups/SMEs
  • 14.7 COMPANY VALUATION & FINANCIAL METRICS
    • 14.7.1 FINANCIAL METRICS
    • 14.7.2 COMPANY VALUATION
  • 14.8 BRAND/PRODUCT COMPARISON
    • 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 DEALS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 NEW ENGLAND BIOLABS
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products offered
      • 15.1.1.3 MnM view
        • 15.1.1.3.1 Key strengths
        • 15.1.1.3.2 Strategic choices
        • 15.1.1.3.3 Weaknesses & competitive threats
    • 15.1.2 THERMO FISHER SCIENTIFIC INC.
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products offered
      • 15.1.2.3 MnM view
        • 15.1.2.3.1 Key strengths
        • 15.1.2.3.2 Strategic choices
        • 15.1.2.3.3 Weaknesses & competitive threats
    • 15.1.3 QIAGEN N.V.
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products offered
      • 15.1.3.3 MnM view
        • 15.1.3.3.1 Key strengths
        • 15.1.3.3.2 Strategic choices
        • 15.1.3.3.3 Weaknesses & competitive threats
    • 15.1.4 PROMEGA CORPORATION
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products offered
      • 15.1.4.3 MnM view
        • 15.1.4.3.1 Key strengths
        • 15.1.4.3.2 Strategic choices
        • 15.1.4.3.3 Weaknesses & competitive threats
    • 15.1.5 TAKARA BIO INC.
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products offered
      • 15.1.5.3 MnM view
        • 15.1.5.3.1 Key strengths
        • 15.1.5.3.2 Strategic choices
        • 15.1.5.3.3 Weaknesses & competitive threats
    • 15.1.6 DANAHER CORPORATION
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products offered
      • 15.1.6.3 MnM view
        • 15.1.6.3.1 Key strengths
        • 15.1.6.3.2 Strategic choices
        • 15.1.6.3.3 Weaknesses & competitive threats
    • 15.1.7 AGILENT TECHNOLOGIES, INC.
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products offered
    • 15.1.8 F. HOFFMANN-LA ROCHE LTD.
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Deals
    • 15.1.9 MERCK KGAA
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products offered
    • 15.1.10 ARCTICZYMES TECHNOLOGIES
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products offered
    • 15.1.11 BIOSYNTH
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products offered
    • 15.1.12 HIMEDIA LABORATORIES
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products offered
    • 15.1.13 LGC BIOSEARCH TECHNOLOGIES
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products offered
    • 15.1.14 INSPIRALIS LIMITED
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products offered
    • 15.1.15 BIONEER CORPORATION
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products offered
  • 15.2 OTHER PLAYERS
    • 15.2.1 GENO TECHNOLOGY INC.
    • 15.2.2 MBR, INC.
    • 15.2.3 ABCLONAL, INC.
    • 15.2.4 NZYTECH
    • 15.2.5 JENA BIOSCIENCE GMBH
    • 15.2.6 CREATIVE ENZYMES.
    • 15.2.7 ENZYNOMICS CO., LTD.
    • 15.2.8 BIOCAT GMBH
    • 15.2.9 GENAXXON BIOSCIENCE
    • 15.2.10 MERIDIAN BIOSICENCE
    • 15.2.11 CANVAX
    • 15.2.12 BIOTECHRABBIT
    • 15.2.13 MCLAB

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 LIGASE ENZYMES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 3 LIGASE ENZMES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 4 LIGASE ENZYMES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
  • TABLE 5 LIGASE ENZYMES MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS
  • TABLE 6 LIGASE ENZYMES MARKET: IMPACT ANALYSIS
  • TABLE 7 LIGASE ENZYMES MARKET: RAW MATERIAL VENDORS
  • TABLE 8 PATENTS APPLIED & GRANTED, 2014-2024
  • TABLE 9 INNOVATIONS & PATENT REGISTRATIONS, 2024
  • TABLE 10 IMPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 11 IMPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (TONS)
  • TABLE 12 EXPORT VALUE OF HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (USD THOUSAND)
  • TABLE 13 EXPORT VOLUME FOR HS CODE 350790-COMPLIANT PRODUCTS FOR TOP 20 COUNTRIES, 2020-2024 (TONS)
  • TABLE 14 LIGASE ENZYMES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 LIGASE ENZYMES MARKET: REGULATORY GUIDELINES
  • TABLE 20 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022-2024
  • TABLE 21 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024 (USD)
  • TABLE 22 LIGASE ENZYMES MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES
  • TABLE 24 BUYING CRITERIA FOR LIGASE ENZYMES, BY END USER
  • TABLE 25 KEY COMPANIES IMPLEMENTING AI IN LIGASE ENZYMES MARKET
  • TABLE 26 LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 27 DNA LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 28 NORTH AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 EUROPE: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 31 LATIN AMERICA: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 MIDDLE EAST: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 GCC COUNTRIES: DNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 RNA LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 EUROPE: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 LATIN AMERICA: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 MIDDLE EAST: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 GCC COUNTRIES: RNA LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 OTHER LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 NORTH AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 EUROPE: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 LATIN AMERICA: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 MIDDLE EAST: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 GCC COUNTRIES: OTHER LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 49 VIRAL LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 NORTH AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 EUROPE: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 LATIN AMERICA: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 MIDDLE EAST: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 GCC COUNTRIES: VIRAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 BACTERIAL LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 EUROPE: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 LATIN AMERICA: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 MIDDLE EAST: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 GCC COUNTRIES: BACTERIAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 EUKARYOTIC LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 EUROPE: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 LATIN AMERICA: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 MIDDLE EAST: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 69 GCC COUNTRIES: EUKARYOTIC LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 70 ARCHAEAL LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 71 NORTH AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 EUROPE: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 LATIN AMERICA: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 75 MIDDLE EAST: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 76 GCC COUNTRIES: ARCHAEAL LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 78 RUO-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 79 NORTH AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 EUROPE: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 83 MIDDLE EAST: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 GCC COUNTRIES: RUO-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 GMP-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 EUROPE: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: GMP-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 EUROPE: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 LATIN AMERICA: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 MIDDLE EAST: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: DIAGNOSTIC-GRADE LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 100 LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 EUROPE: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 LATIN AMERICA: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 MIDDLE EAST: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR CLONING & MUTAGENESIS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 EUROPE: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SYNTHETIC BIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 LIGASE ENZYMES MARKET FOR SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 122 NORTH AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 EUROPE: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 LATIN AMERICA: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 MIDDLE EAST: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR NUCLEIC ACID AMPLIFICATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 129 LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 EUROPE: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 LATIN AMERICA: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 MIDDLE EAST: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 137 NORTH AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 EUROPE: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 MIDDLE EAST: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 144 NORTH AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 145 EUROPE: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 LATIN AMERICA: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 MIDDLE EAST: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR THERAPEUTIC DEVELOPMENT & MANUFACTURING APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 NORTH AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 152 EUROPE: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 158 LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 159 NORTH AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 EUROPE: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 LATIN AMERICA: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 MIDDLE EAST: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 164 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 165 LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 166 NORTH AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 EUROPE: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 LATIN AMERICA: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 171 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 172 LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 173 NORTH AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 EUROPE: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 176 LATIN AMERICA: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 177 MIDDLE EAST: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 179 LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 180 NORTH AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 EUROPE: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 183 LATIN AMERICA: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 184 MIDDLE EAST: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 185 GCC COUNTRIES: LIGASE ENZYMES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 LIGASE ENZYMES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 187 NORTH AMERICA: LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 189 NORTH AMERICA: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 190 NORTH AMERICA: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 191 NORTH AMERICA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 192 NORTH AMERICA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 193 NORTH AMERICA: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 194 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 195 US: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 196 US: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 197 US: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 198 US: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 199 US: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 200 US: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 201 CANADA: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 202 CANADA: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 203 CANADA: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 204 CANADA: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 205 CANADA: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 206 CANADA: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 207 EUROPE: LIGASE ENZYMES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 208 EUROPE: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 EUROPE: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 210 EUROPE: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 211 EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 212 EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 213 EUROPE: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 214 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 215 GERMANY: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 216 GERMANY: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 217 GERMANY: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 218 GERMANY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 219 GERMANY: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 220 GERMANY: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 221 UK: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 222 UK: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 223 UK: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 224 UK: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 225 UK: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 226 UK: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 227 FRANCE: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 FRANCE: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 229 FRANCE: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 230 FRANCE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 231 FRANCE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 232 FRANCE: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 233 ITALY: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 234 ITALY: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 235 ITALY: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 236 ITALY: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 237 ITALY: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 238 ITALY: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 239 SPAIN: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 240 SPAIN: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 241 SPAIN: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 242 SPAIN: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 243 SPAIN: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 244 SPAIN: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 245 REST OF EUROPE: LIGASE ENZYMES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 REST OF EUROPE: LIGASE ENZYMES MARKET, BY GRADE, 2023-2030 (USD MILLION)
  • TABLE 247 REST OF EUROPE: LIGASE ENZYMES MARKET, BY SOURCE, 2023-2030 (USD MILLION)
  • TABLE 248 REST OF EUROPE: LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 249 REST OF EUROPE: LIGASE ENZYMES MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 250 REST OF EUROPE: LIGASE ENZYMES MARKET, BY END USER, 2023-2030 (USD MILLION)

List of Figures

  • FIGURE 1 LIGASE ENZYMES MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN METHODOLOGY
  • FIGURE 3 LIGASE ENZYMES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 GLOBAL LIGASE ENZYMES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 9 LIGASE ENZYMES MARKET: CAGR PROJECTIONS, 2025-2030
  • FIGURE 10 LIGASE ENZYMES MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 LIGASE ENZYMES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 LIGASE ENZYMES MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 LIGASE ENZYMES MARKET, BY GRADE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 LIGASE ENZYMES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 LIGASE ENZYMES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 REGIONAL SNAPSHOT OF LIGASE ENZYMES MARKET
  • FIGURE 19 RISING GENOMCS & NGS ACTIVITIES TO PROPEL MARKET GROWTH
  • FIGURE 20 US AND DNA LIGASES COMMANDED LARGER MARKET SHARES IN 2024
  • FIGURE 21 DNA LIGASES ACCOUNTED FOR LARGEST SHARE OF LIGASE ENZYMES MARKET IN 2024
  • FIGURE 22 ACADEMIC & RESEARCH INSTITUTES SEGMENT HELD LARGEST MARKET SHARE IN 2024
  • FIGURE 23 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
  • FIGURE 24 LIGASE ENZYMES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 26 LIGASE ENZYMES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 LIGASE ENZYMES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 28 PATENT APPLICATIONS IN LIGASE ENZYMES MARKET, JANUARY 2014-DECEMBER 2024
  • FIGURE 29 LIGASE ENZYMES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 30 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022-2024
  • FIGURE 31 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024
  • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIGASE ENZYMES
  • FIGURE 33 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 34 AI USE CASES
  • FIGURE 35 NORTH AMERICA: LIGASE ENZYMES MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: LIGASE ENZYMES MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2020-2024
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LIGASE ENZYMES MARKET, 2024
  • FIGURE 39 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 40 LIGASE ENZYMES MARKET: COMPANY FOOTPRINT
  • FIGURE 41 LIGASE ENZYMES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 LIGASE ENZYMES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT (2024)
  • FIGURE 52 ARCTICZYMES TECHNOLOGIES: COMPANY SNAPSHOT (2024)